Rapt Therapeutics Stock Today
| RAPT Stock | USD 1.05 0.02 1.87% |
Performance0 of 100
| Odds Of DistressOver 64
|
RAPT Therapeutics is selling for under 1.05 as of the 21st of November 2024; that is 1.87 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.0. RAPT Therapeutics has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for RAPT Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of October 2019 | Category Healthcare | Classification Health Care |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. The company has 34.96 M outstanding shares of which 2.67 M shares are at this time shorted by private and institutional investors with about 9.95 trading days to cover. More on RAPT Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
RAPT Stock Highlights
| President CEO | Brian MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRAPT Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand RAPT Therapeutics' financial leverage. It provides some insight into what part of RAPT Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAPT Therapeutics (RAPT) is traded on NASDAQ Exchange in USA. It is located in 561 Eccles Avenue, South San Francisco, CA, United States, 94080 and employs 70 people. RAPT Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.41 M. RAPT Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.96 M outstanding shares of which 2.67 M shares are at this time shorted by private and institutional investors with about 9.95 trading days to cover.
RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check RAPT Therapeutics Probability Of Bankruptcy
Ownership AllocationRAPT Therapeutics owns a total of 34.96 Million outstanding shares. The majority of RAPT Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in RAPT Therapeutics to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in RAPT Therapeutics. Please pay attention to any change in the institutional holdings of RAPT Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check RAPT Ownership Details
RAPT Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-06-30 | 698.4 K | |
| Geode Capital Management, Llc | 2024-06-30 | 684.7 K | |
| State Street Corp | 2024-06-30 | 671.8 K | |
| Euclidean Capital Llc | 2024-06-30 | 657.9 K | |
| Two Sigma Investments Llc | 2024-06-30 | 612.3 K | |
| Alphabet Inc | 2024-06-30 | 540.3 K | |
| Redmile Group, Llc | 2024-09-30 | 504.5 K | |
| Ardsley Advisory Partners | 2024-06-30 | 500 K | |
| Cormorant Asset Management, Llc | 2024-06-30 | 496.8 K | |
| Fmr Inc | 2024-09-30 | 5.2 M | |
| Vanguard Group Inc | 2024-09-30 | 3.2 M |
RAPT Therapeutics Historical Income Statement
RAPT Stock Against Markets
RAPT Therapeutics Corporate Management
| Gwen Carscadden | Chief Officer | Profile | |
| Rodney Young | Principal CFO | Profile | |
| David Wustrow | Senior Development | Profile | |
| William Ho | Chief Officer | Profile | |
| Jennifer Nicholson | Senior Assurance | Profile | |
| Michael Listgarten | General Counsel | Profile | |
| William MD | Chief Officer | Profile |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.